Free Trial

Edwards Lifesciences (NYSE:EW) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Edwards Lifesciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wells Fargo raised its Edwards Lifesciences price target from $113 to $121 and maintained an Overweight rating, implying 12.9% upside from the previous close.
  • Analyst sentiment is broadly positive: 23 analysts rate the stock Buy and three rate it Hold, with an average price target of $109.88.
  • Edwards beat quarterly expectations, reporting EPS of $0.80 versus $0.74 expected and revenue of $1.72 billion, up 10.5% year over year.
  • Five stocks we like better than Edwards Lifesciences.

Edwards Lifesciences (NYSE:EW - Get Free Report) had its price objective boosted by equities researchers at Wells Fargo & Company from $113.00 to $121.00 in a report issued on Monday, Benzinga reports. The brokerage currently has an "overweight" rating on the medical research company's stock. Wells Fargo & Company's target price suggests a potential upside of 12.91% from the stock's previous close.

A number of other analysts have also weighed in on EW. Robert W. Baird upgraded shares of Edwards Lifesciences from a "neutral" rating to an "outperform" rating and set a $116.00 target price for the company in a report on Thursday, November 5th. UBS Group boosted their price target on Edwards Lifesciences from $110.00 to $118.00 and gave the company a "buy" rating in a report on Thursday, November 5th. Royal Bank Of Canada upped their price target on Edwards Lifesciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research report on Thursday, November 5th. Evercore reiterated an "outperform" rating on shares of Edwards Lifesciences in a report on Friday, October 23rd. Finally, Barclays increased their price objective on Edwards Lifesciences from $110.00 to $120.00 and gave the stock an "overweight" rating in a report on Thursday, November 5th. Twenty-three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $109.88.

View Our Latest Report on EW

Edwards Lifesciences Stock Up 0.0%

Shares of NYSE EW opened at $107.16 on Monday. The company has a quick ratio of 3.86, a current ratio of 4.60 and a debt-to-equity ratio of 0.05. Edwards Lifesciences has a 52 week low of $74.66 and a 52 week high of $107.69. The firm's fifty day moving average is $90.42 and its 200 day moving average is $86.32. The company has a market cap of $61.62 billion, a price-to-earnings ratio of 60.54, a PEG ratio of 2.86 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.80 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.06. The company had revenue of $1.72 billion during the quarter, compared to analyst estimates of $1.68 billion. Edwards Lifesciences had a net margin of 15.30% and a return on equity of 16.06%. The firm's revenue was up 10.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.67 EPS. On average, equities research analysts expect that Edwards Lifesciences will post 3.01 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other news, SVP Andrew M. Dahl sold 544 shares of Edwards Lifesciences stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $91.06, for a total transaction of $49,536.64. Following the sale, the senior vice president owned 14,868 shares of the company's stock, valued at approximately $1,353,880.08. The trade was a 3.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Donald Bobo, Jr sold 48,900 shares of the business's stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $103.05, for a total transaction of $5,039,145.00. Following the transaction, the vice president owned 22,798 shares in the company, valued at $2,349,333.90. This represents a 68.20% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 53,945 shares of company stock worth $5,498,306. 0.31% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Legacy Trust lifted its holdings in Edwards Lifesciences by 1.4% in the 3rd quarter. Legacy Trust now owns 7,409 shares of the medical research company's stock valued at $682,000 after purchasing an additional 104 shares in the last quarter. Bessemer Group Inc. boosted its stake in Edwards Lifesciences by 0.4% during the 3rd quarter. Bessemer Group Inc. now owns 28,358 shares of the medical research company's stock worth $2,447,000 after purchasing an additional 114 shares during the last quarter. Harbour Wealth Management Group Inc. grew its holdings in shares of Edwards Lifesciences by 3.9% during the third quarter. Harbour Wealth Management Group Inc. now owns 3,070 shares of the medical research company's stock worth $265,000 after buying an additional 114 shares in the last quarter. Flagship Harbor Advisors LLC grew its holdings in shares of Edwards Lifesciences by 1.2% during the third quarter. Flagship Harbor Advisors LLC now owns 10,615 shares of the medical research company's stock worth $916,000 after buying an additional 125 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC grew its holdings in shares of Edwards Lifesciences by 1.8% during the third quarter. Fifth Third Wealth Advisors LLC now owns 7,268 shares of the medical research company's stock worth $627,000 after buying an additional 132 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Company Profile

(Get Free Report)

Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.

Further Reading

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Edwards Lifesciences Right Now?

Before you consider Edwards Lifesciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.

While Edwards Lifesciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines